Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine.

ABSTRACT: Spinal muscular atrophy (SMA) is a devastating childhood motor neuron disease that, in the most severe cases and when left untreated, leads to death within the first two years of life. Recent therapeutic advances have given hope to families and patients by compensating for the deficiency in survival motor neuron (SMN) protein via gene therapy or other genetic manipulation. However, it is now apparent that none of these therapies will cure SMA alone. In this review, we discuss the three currently licensed therapies for SMA, briefly highlighting their respective advantages and disadvantages, before considering alternative approaches to increasing SMN protein levels. We then explore recent preclinical research that is identifying and targeting dysregulated pathways secondary to, or independen

SUBMITTER: Chaytow H 

PROVIDER: S-EPMC8324491 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature